WO1998021321A1 - Procede d'identification des genes regules par traduction - Google Patents
Procede d'identification des genes regules par traduction Download PDFInfo
- Publication number
- WO1998021321A1 WO1998021321A1 PCT/US1997/020831 US9720831W WO9821321A1 WO 1998021321 A1 WO1998021321 A1 WO 1998021321A1 US 9720831 W US9720831 W US 9720831W WO 9821321 A1 WO9821321 A1 WO 9821321A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mrna
- set forth
- genes
- translation
- cells
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 127
- 238000000034 method Methods 0.000 title claims abstract description 126
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 54
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 169
- 238000013519 translation Methods 0.000 claims abstract description 66
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims abstract description 31
- 230000001939 inductive effect Effects 0.000 claims abstract description 30
- 230000004936 stimulating effect Effects 0.000 claims abstract description 15
- 230000001419 dependent effect Effects 0.000 claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 94
- 108020004707 nucleic acids Proteins 0.000 claims description 64
- 102000039446 nucleic acids Human genes 0.000 claims description 64
- 150000007523 nucleic acids Chemical class 0.000 claims description 64
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 45
- 108010079304 Picornavirus picornain 2A Proteins 0.000 claims description 41
- 230000014509 gene expression Effects 0.000 claims description 40
- 238000004458 analytical method Methods 0.000 claims description 35
- 210000001519 tissue Anatomy 0.000 claims description 34
- 238000009396 hybridization Methods 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 238000010367 cloning Methods 0.000 claims description 11
- 230000001575 pathological effect Effects 0.000 claims description 10
- 238000002493 microarray Methods 0.000 claims description 9
- 230000007170 pathology Effects 0.000 claims description 7
- 238000012163 sequencing technique Methods 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 238000005516 engineering process Methods 0.000 claims description 6
- 238000013518 transcription Methods 0.000 claims description 6
- 230000035897 transcription Effects 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 244000052769 pathogen Species 0.000 claims description 5
- 230000033228 biological regulation Effects 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 210000000805 cytoplasm Anatomy 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 2
- 238000003196 serial analysis of gene expression Methods 0.000 claims 4
- 230000001678 irradiating effect Effects 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 230000001276 controlling effect Effects 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 238000010208 microarray analysis Methods 0.000 claims 1
- 230000026447 protein localization Effects 0.000 claims 1
- 239000002585 base Substances 0.000 description 30
- 239000000523 sample Substances 0.000 description 27
- 239000002299 complementary DNA Substances 0.000 description 25
- 230000035882 stress Effects 0.000 description 21
- 239000000499 gel Substances 0.000 description 16
- 238000002955 isolation Methods 0.000 description 16
- 229930006000 Sucrose Natural products 0.000 description 15
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 15
- 230000008859 change Effects 0.000 description 15
- 230000007246 mechanism Effects 0.000 description 15
- 239000005720 sucrose Substances 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 210000002729 polyribosome Anatomy 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 238000005194 fractionation Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 102100021231 Pre-mRNA-processing-splicing factor 8 Human genes 0.000 description 9
- 101710107530 Ral GTPase-activating protein subunit alpha-2 Proteins 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 230000014621 translational initiation Effects 0.000 description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 230000035939 shock Effects 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 7
- 239000004365 Protease Substances 0.000 description 7
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 235000019419 proteases Nutrition 0.000 description 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 230000000977 initiatory effect Effects 0.000 description 6
- 229910001868 water Inorganic materials 0.000 description 6
- 108020004635 Complementary DNA Proteins 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- 108091023045 Untranslated Region Proteins 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000007954 hypoxia Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 210000003705 ribosome Anatomy 0.000 description 5
- 108020003589 5' Untranslated Regions Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000010195 expression analysis Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 3
- 102100037362 Fibronectin Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 3
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 3
- 102000007999 Nuclear Proteins Human genes 0.000 description 3
- 108010089610 Nuclear Proteins Proteins 0.000 description 3
- 102000013009 Pyruvate Kinase Human genes 0.000 description 3
- 108020005115 Pyruvate Kinase Proteins 0.000 description 3
- 238000010240 RT-PCR analysis Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000003436 cytoskeletal effect Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 230000006164 hypusine formation Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 102100032488 Acylamino-acid-releasing enzyme Human genes 0.000 description 2
- 108010061216 Acylaminoacyl-peptidase Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 102100023981 Lamina-associated polypeptide 2, isoform alpha Human genes 0.000 description 2
- 101710163560 Lamina-associated polypeptide 2, isoform alpha Proteins 0.000 description 2
- 101710189385 Lamina-associated polypeptide 2, isoforms beta/gamma Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 2
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 2
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 2
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108010034634 Repressor Proteins Proteins 0.000 description 2
- 102000002278 Ribosomal Proteins Human genes 0.000 description 2
- 108010000605 Ribosomal Proteins Proteins 0.000 description 2
- 108010019965 Spectrin Proteins 0.000 description 2
- 102000005890 Spectrin Human genes 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 239000000898 Thymopoietin Substances 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000009274 differential gene expression Effects 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 210000004265 eukaryotic small ribosome subunit Anatomy 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- NLIVDORGVGAOOJ-MAHBNPEESA-M xylene cyanol Chemical compound [Na+].C1=C(C)C(NCC)=CC=C1C(\C=1C(=CC(OS([O-])=O)=CC=1)OS([O-])=O)=C\1C=C(C)\C(=[NH+]/CC)\C=C/1 NLIVDORGVGAOOJ-MAHBNPEESA-M 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000005758 Adenosylmethionine decarboxylase Human genes 0.000 description 1
- 108010070753 Adenosylmethionine decarboxylase Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 101710147945 Cytochrome b-c1 complex subunit 6 Proteins 0.000 description 1
- 101710146285 Cytochrome b-c1 complex subunit 6, mitochondrial Proteins 0.000 description 1
- 102100039455 Cytochrome b-c1 complex subunit 6, mitochondrial Human genes 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 102100038199 Desmoplakin Human genes 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010013142 Disinhibition Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102100039737 Eukaryotic translation initiation factor 4 gamma 2 Human genes 0.000 description 1
- 102100026761 Eukaryotic translation initiation factor 5A-1 Human genes 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 101150098893 GEM gene Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 1
- 101000883444 Homo sapiens Desmoplakin Proteins 0.000 description 1
- 101001034811 Homo sapiens Eukaryotic translation initiation factor 4 gamma 2 Proteins 0.000 description 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
- 101000691574 Homo sapiens Junction plakoglobin Proteins 0.000 description 1
- 101100203078 Homo sapiens SF3B6 gene Proteins 0.000 description 1
- 102100026153 Junction plakoglobin Human genes 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 101000870233 Manduca sexta Diuretic hormone 2 Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108091060294 Messenger RNP Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- PCNLLVFKBKMRDB-UHFFFAOYSA-N N-ethyl-N-[[2-(1-pentylindol-3-yl)-1,3-thiazol-4-yl]methyl]ethanamine Chemical compound C(C)N(CC=1N=C(SC=1)C1=CN(C2=CC=CC=C12)CCCCC)CC PCNLLVFKBKMRDB-UHFFFAOYSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101100256131 Oryza sativa subsp. japonica SAP14 gene Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 1
- 206010071368 Psychological trauma Diseases 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 101000592082 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L28 Proteins 0.000 description 1
- 102000017852 Saposin Human genes 0.000 description 1
- 108050007079 Saposin Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101800002927 Small subunit Proteins 0.000 description 1
- 102100021817 Splicing factor 3B subunit 6 Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 108091092330 cytoplasmic RNA Proteins 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000009025 developmental regulation Effects 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 230000007959 normoxia Effects 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 108020003519 protein disulfide isomerase Proteins 0.000 description 1
- 238000011155 quantitative monitoring Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1051—Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
Definitions
- the present invention relates to a method for identifying genes that are translationally regulated. More specifically, the present invention relates to the rapid isolation of differentially expressed or developmentally regulated gene sequences through segregation of mRNAs into translated and untranslated pools and comparing the relative abundance of the mRNAs found in these pools by differential analysis.
- coli are transformed with the cDNA containing vectors, linearized fragments are generated from the cloned inserts by digestion with at least one restriction endonuclease that is different from the first and second restriction endonucleouseases and a cDNA preparation of the anti-sense cDNA transcripts is generated by incubating the linearized fragments with a T3 RNA polymerase.
- the cDNA population is divided into subpools and the first strand cDNA from each subpool is transcribed using a thermostable reverse transcriptase and one of sixteen primers.
- the transcription product of each of the sixteen reaction pools is used as a template for a polymerase chain reaction (PCR) with a 3'-primer and a 5'-primer and the polymerase chain reaction amplified fragments are resolved by electrophoresis to display bands representing the 3 '-ends of the mRNAs present in the sample.
- PCR polymerase chain reaction
- This method is useful for the identification of differentially expressed mRNAs and the measurement of their relative concentrations. This type of methodology, however, is unable to identify mRNAs whose levels remain constant but their translatability is variable or changes.
- Schena et al. developed a high capacity system to monitor the expression of many genes in parallel utilizing microarrays.
- the microarrays are prepared by high speed robotic printing of cDNAs on glass providing quantitative expression measurements of the corresponding genes (Schena et al., 1995). Differential expression measurements of genes are made by means of simultaneous, two color fluorescence hybridization. However, this method alone is insufficient for the identification of translationally regulated genes.
- the translation of eukaryotic mRNAs is dependent upon 5' cap-mediated ribosome binding.
- the ribosome small sub- unit (40S) binds to the 5'-cap structure on a transcript and then proceeds to scan along the mRNA molecule to the translation initiation site where the large sub-unit (60S) forms the complete ribosome initiation site.
- the translation initiation site is the first AUG codon.
- IRES containing mRNA transcripts have been discovered in non-viral systems such as the mRNA encoding for immunoglobulin heavy chain binding protein, the antenapedia gene in Drosophila, and the mouse Fgl-2 gene. These discoveries have promoted speculation for the role of cap- independent translation in the developmental regulation of gene expression during both normal and abnormal processes.
- a method for identifying translationally regulated genes in an organism including the steps of selectively stimulating translation of an unknown target mRNA with a stress inducing element, the target mRNA being part of a larger sample of mRNA, dividing the sample of mRNA into pools of translated and untranslated mRNA and differentially analyzing the pools of mRNA to identify genes translationally regulated by the stress inducing element.
- the stress inducing element can include pathologic, environmental including chemical and physical stressors or other stimulus that induces mRNA translation.
- a method for identifying gene sequences coding for internal ribosome entry sites are provided.
- the method includes inhibiting 5 'cap-dependant mRNA translation in a cell, collecting a pool of mRNA from the cells, and differentially analyzing the pool of mRNA to identify genes with sequences coding for internal ribosome entry sites.
- Figure 1 A is an absorbance profile of a fractionation of cytoplasmic
- RNA on a sucrose density gradient wherein the absorbance (at 254nm) is plotted against the sedimentation rate of the cytoplasmic RNA
- Figure IB is a photograph of purified RNA electrophoresed on an agarous gel and stained with ethidium bromide illustrating the fractionation of RNA;
- Figure 2 is a photograph of a 5% acrylamide gel illustrating a differential translation analysis of mRNA from sucrose density gradients according to the present invention
- Figure 3A-C are schematic representations of plasmids that contain the Polio virus 2 A genes (A) in plasmid pTK-OP3-WT2A, (B) in the plasmid miniTK-WT2A, and (C) in a plasmid containing a hygromycin selectable marker;
- Figure 4 is graph illustrating the induction of Polio virus 2A protease leading to cell death after induction of the 2A protease;
- Figure 5 is a photograph of a gel illustrating the presence of Polio virus 2A protease expression in transformed HEK-293 cells (293-2A) following induction with IPTG and the absence of the Polio virus 2 A protease in HEK-293 (293) parental cells following treatment with IPTG; and
- Figure 6 is a photograph of a Western blot illustrating the activity of the Polio virus 2A protease in cleaving the p220 protein component of the 40S ribosomal subunit demonstrating that clones which were induced for Polio virus
- the present invention provides a method for identifying translationally regulated genes in an organism by selectively stimulating translation of an unknown target mRNA with a stress inducing element, the target mRNA being part of a larger sample.
- the organism may be any organism which provides suitable mRNA.
- the mRNA sample is divided into pools of translated and untranslated mRNA which are differentially analyzed to identify genes which are translationally regulated by the stress inducing element.
- This method is designed for identifying and cloning genes which are regulated at the translational level. That is, the present method is designed for identifying and cloning genes which are either up- or down- regulated including identifying genes responsive to a specific pathology or stress condition.
- the method of the present invention provides a novel approach to the identification and cloning of genes that are involved in fundamental cellular functions and which are regulated at the level of translation in an organism.
- the basic underlying theory for this method relies on the assumption that an mRNA encoding a protein required for a quick response to an external cue is generally stored as an untranslated mRNA. Following the appropriate external cue, the mRNA is translated and the encoded protein quickly appears. By comparing mRNA populations that are "active” or "non-active" at a given time, genes that are regulated by a mechanism referred to as the "shift mechanism" can be identified.
- the method can also be applied to identify in addition to genes regulated at the translational level; genes regulated at the transcription level; genes regulated by RNA stability; gene regulated by mRNA transport rate between the nucleus and the cytoplasm; and gene regulated by differential splicing. That is, genes whose expression in part, is controlled/regulated at the mRNA level can be identified.
- the method will identify genes encoding secreted and membrane proteins; genes encoding for nuclear proteins; genes encoding for mitochondrial proteins; and genes encoding for cytoskeletal proteins. In addition, any other gene whose expression can be controlled at the mRNA level can be identified by this method.
- RNA refers to RNA isolated from cell cultures, cultured tissues or cells or tissues isolated from organisms which are stimulated, differentiated, exposed to a chemical compound, are infected with a pathogen or otherwise stimulated.
- translation is defined as the synthesis of protein on an mRNA template.
- stimulating translation of unknown target mRNA or stimulating element includes chemically, pathogenically, physically, or otherwise inducing or repressing an mRNA population from genes which can be derived from native tissues and/or cells under pathological and/or stress conditions that are regulated by the "shift mechanism.”
- stimulating the translation of mRNA with a stress inducing element or "stressor” can include the application of an external cue, stimulus, or stimuli which stimulates or initiates translation of a mRNA stored as untranslated mRNA in the cells from the sample.
- stimulation can include induction and/or repression of genes under pathological and/or stress conditions.
- the present method utilizes a stimulus or stressor to identify unknown target genes which are translationally regulated by the stress inducing element or stressor.
- the method of the present invention integrates two previously known methodologies which were otherwise used separately.
- the first method is the division of an mRNA sample into separate translated and untranslated pools of mRNA.
- the second methodology involves the simultaneous comparison of the relative abundance of the mRNA species found in the separate pools by a method of differential analysis such as differential display, representational difference analysis (RDA), gene expression microarray (GEM), suppressive subtraction hybridization (SSH) (Diatchenko et al., 1996), and techniques such as chip technology exemplified by United States Patent No. 5,545,531 to Rava et al. assigned to Affymax Technologies N.V. and direct sequencing exemplified by WO
- RDA representational difference analysis
- GEM gene expression microarray
- SSH suppressive subtraction hybridization
- subtractive hybridization is defined as subtraction of mRNA by hybridization in solution. RNA that are common to the two pools form a duplex that can be removed, enriching for RNAs that are unique or more abundant in one pool.
- Differential Display is defined as reverse transcription of mRNA into cDNA and PCR amplification with degenerated primers. Comparison of the amounts amplification products (by electrophoresis) from two pools indicate transcript abundance. RDA, GEM, SSH, SAGE are described herein above.
- the specific cells/tissues which are to be analyzed in order to identify translationally regulated genes can include any suitable cells and/or tissues. Any cell type or tissue can be used, whether an established cell line or culture or whether directly isolated from an exposed organism.
- the cells/tissues to be analyzed under the present method are selectively stimulated utilizing a physiological, chemical, environmental and/or pathological stress inducing element or stressor, in order to stimulate the translation of mRNA within the sample tissue and identify genes whose expression is regulated at least in part at the mRNA level.
- the RNA from the cells/tissues is isolated or extracted from the cells/tissues. The isolation of the RNA can be performed utilizing techniques which are well known to those skilled in the art and are described, for example, in
- the mRNAs which are actively engaged in translation and those which remain untranslated can be separated utilizing a procedure such as fractionation on a sucrose density gradient, high performance gel filtration chromatography, or polyacrylamide gel matrix separation (Ogishima et al., 1984, Menaker et al., 1974, Hirama et al., 1986, Mechler, 1987, and Bharucha and Murthy, 1992), since mRNAs that are being translated are loaded with ribosomes and, therefore, will migrate differently on a density gradient than ribosome-free untranslated mRNAs.
- genes that are regulated by the "shift mechanism" can be identified.
- Polysomal fractionation and specific analysis can be facilitated by treatment of target cell/tissue with drugs that will specifically inhibit or modulate transcription or translation. Examples of such drugs are actinomycin D and cyclohexamide, respectively.
- the fractionation can be completed to create polysomal subdivisions.
- the subdivisions can be made to discriminate between total polyribosomes or membrane bound ribosomes by methods known in the art
- the mRNA sample can be in addition fractionated into one or more of at least the following subsegments or fractions: cytoplasmatic, nuclear, polyribosomal, sub polyribosomal, microsomal or rough endoplasmic reticulum, mitochondrial and splicesome associated mRNA by methods known in the art (see also Table 1).
- differential analysis technique such as differential display, representational difference analysis (RDA), GEM-Gene Expression Microarrays (Schena et al.,
- RNA isolated from the fractions can be further purified into mRNA without the ribosomal RNA by poly A selection. It should be noted that multiple pools can be analyzed utilizing this method. That is, different cell aliquots subjected to different stressors can be compared with each other as well as with the reference sample.
- Labeled mRNA in a cDNA or PCR product form
- polysomal, non-polysomal or mRNPs pools or individual fractions
- label can be radioactive, fluorescent, or incorporating a modified base such as digoxigenin and biotin.
- the polysomal fractions or groups can include membrane bound polysomes, loose or tight polysomes, or free unbound polysome groups.
- Example 2 The importance of utilizing the polysomal sub-population in order to identify differentially (translationally) expressed genes is shown in Example 2 where a number of genes were not detected as translationally expressed under heat shock inducement when total mRNA was used as the detection probe but, however, when polysomal mRNA was used as a probe, a number of genes were identified as differentially expressed. These genes were previously thought to be non- differentially expressed when total mRNA was used as a probe. That is, as shown in Example 2, a number of genes that were not detected as translationally expressed under heat shock inducement with total mRNA were detected when probed with polysomal mRNA fractions.
- the present method for identifying translationally regulated genes is not limited by the source of the mRNA pools. Therefore, the present method can be utilized to clone genes from native cells/tissue under pathological and/or stress conditions that are regulated by the "shift mechanism," as well as genes that are induced/repressed under pathological and/or stress conditions.
- Pathologies can include disease states including those diseases caused by pathogens and trauma. Stress conditions can also include disease states, physical and psychological trauma, and environmental stresses.
- the genes which have been identified as being regulated by translation can be cloned by any suitable cloning methodologies known to those skilled in the art. (Lisitsyn and Wigler, 1993).
- Differential comparisons can also include polysomal vs. non- polysomal fractions in each condition.
- condition it is meant that cells from the same source, such as a cell line, a primary cell, or a tissue that undergoes different treatment or has been modified to have different features or to express different sets of genes. For example, this can be accomplished by differentiation, transformation, application of the stress such as oxygen deprivation, chemical treatment, or radiation. Permutations can include, for example:
- each of the fractions being polysomal and non-polysomal individually (migrating in the same density) or in a pool that can be compared to total RNA that is unfractionated.
- the method described above for the identification of translationally regulated genes has a number of applications. A particular application for this method is its use for the detection of changes in the pattern of mRNA expression in cells/tissue associated with any physiological or pathological change. By comparing the translated versus untranslated mRNAs, the effect of the physiological or pathological cue or stress on the change of the pattern of mRNA expression in the cell/tissue can be observed and/or detected.
- This method can be used to study the effects of a number of cues, stimuli, or stressors to ascertain their effect or contribution to various physiological and pathological activities of the cell/tissue.
- the present method can be used to analyze the results of the administrations of pharmaceuticals (drugs) or other chemicals to an individual by comparing the mRNA pattern of a tissue before and after the administration of the drug or chemical. This analysis allows for the identification of drugs, chemicals, or other stimuli which affect cells/tissue at the level of translational regulation.
- a further embodiment of the present invention provides a method for identifying gene sequences coding for internal ribosome entry sites (IRES) and includes the general steps of inhibiting 5 'cap-dependant mRNA translation in a cell, collecting a pool of mRNA from the cells, and differentially analyzing the pool of mRNA to identify genes with sequences coding for internal ribosome entry sites.
- IRS internal ribosome entry sites
- the mechanism(s) of standard scanning-type translation initiation should be substantially, if not totally, turned off or shut down to, in essence, shift the translation equilibrium in favor of IRES initiated translation. That is, recognition of the 5'-cap structure is inhibited by disrupting the normal mechanism for 5'-cap mediated initiation.
- the mechanism for inhibiting the 5'-cap translation can include any known means or mechanisms for preventing the initiation of 5 '-cap mediated translation.
- One such mechanism for inhibiting 5 '-cap mediated translation is the expression of Polio virus 2 A protease into a cell, cell system, or tissue to be analyzed for the presence of IRES sequences.
- Polio virus 2 A protease inhibits 5 '-cap-dependent mRNA translation by inactivating the cellular 5 '-cap-dependent translation machinery. This enables the identification of cellular IRES containing genes which may be translationally controlled and play a critical role in the immediate response of the cell following the application of a stress inducing element/stressor such as heat shock, hypoxia, or other stress inducing elements as set forth above, prior to gene activation.
- the Polio virus 2A protease prevents 5 '-cap-mediated translation by cleaving the large sub-unit of elF- 4 ⁇ (p220) of eukaryotic translation initiation factor 4 (eIF-4) which is involved in the recognition of the mRNA 5'-cap.
- the Polio virus 2A protease In order to inhibit the 5 '-cap-mediated translation, the Polio virus 2A protease must be incorporated into the cell or cells being analyzed for the presence of gene sequences coding for internal ribosome entry sites and/or for identifying translationally regulated genes.
- One such method for incorporating the Polio virus 2A protease In order to inhibit the 5 '-cap-mediated translation, the Polio virus 2A protease must be incorporated into the cell or cells being analyzed for the presence of gene sequences coding for internal ribosome entry sites and/or for identifying translationally regulated genes.
- One such method for incorporating the Polio virus 2A protease must be incorporated into the cell or cells being analyzed for the presence of gene sequences coding for internal ribosome entry sites and/or for identifying translationally regulated genes.
- Polio virus 2A protease into a cell involves the transformation of a target cell with an expression vector containing the gene which codes for the Polio virus 2A protease. Because the Polio virus 2A protease is deleterious to living cells when it is constitutively expressed, the expression vector containing the Polio virus 2A protease gene is coupled with a bacterial Lad inducible system wherein a Lad repressor is constituitively expressed under a CMV promoter.
- the Polio virus 2A protease may be expressed under a number of suitable promoters including the RSV, the TK, or the mini-TK promoter coupled at their 3' end to the Lad repressor binding sites.
- the expression of the Polio virus 2 A protease can be induced upon treatment of the cells with isopropyl- ⁇ -D-thiogalatopyranoside (IPTG).
- IPTG isopropyl- ⁇ -D-thiogalatopyranoside
- Treatment of the target cells with IPTG relieves the binding of the Lad repressor molecules bound at the repressor binding sites thus enabling transcription of the Polio virus 2A protease.
- IPTG isopropyl- ⁇ -D-thiogalatopyranoside
- RNA presumably containing internal ribosome entry sites, can be collected and analyzed utilizing the methods described above to identify genes whose translation is up-regulated by the effects of the Polio virus 2A protease.
- RNA-lysis of cells from a tissue or a cell line
- hypotonic buffer Collection of nuclei by centrifugation and organic extraction of the RNA.
- Polyribosomal/subpolyribosomal fractionation Lysis of cells by homogenization hypotonic buffer, removal of nuclei and fractionation of polyribosome on linear sucrose gradients and organic extraction of the RNA from each fraction of the gradient.
- Secreted and membrane encoding transcripts secreted and membrane encoding transcripts.
- X-100 and 0.2M sucrose was added.
- the cells were homogenized with a Dounce homogenizer (five strokes with B pestle).
- the cell lysate was centrifuged at 2300g for ten minutes at 4°C.
- the supernatant was transferred to a new tube.
- HLB containing lOmg/ml heparin was added to a final concentration of lmg/ml heparin.
- NaCl was added to a final concentration of 0.15M.
- the supernatant was frozen at
- a linear sucrose gradient from 0.5M to 1.5M sucrose in HLB was prepared. Polyallomer tubes (14X89mm) were used. 0.5 to 1.0ml of cell extract was loaded on the gradient. The cells were centrifuged at 36,000 RPM for 110 minutes at 4°C.
- RNA purification SDS was added to 0.5% and Proteinase K to O.lmg/ml and incubated at 37°C for
- DEPC DEPC-treated water
- each reaction is done in 20 ⁇ l and contains 50 ⁇ M dNTP mix, l ⁇ M from each primer, lx polymerase buffer, 1 unit expand Polymerase
- oligonucleotides are used in this procedure: R-Bgl-12 5' GATCTGCGGTGA 3' (SEQ ID No: 22) R-Bgl-24 5' AGCACTCTCCAGCCTCTCACCGCA 3' (SEQ ID No:23) J-Bgl-12 5' GATCTGTTCATG 3' (SEQ ID No: 24)
- R-Bgl-12 and R-Bgl-24 oligos were ligated to Tester and Driver: 1.2 ⁇ g DpnII digested cDNA. 4 ⁇ l from each oligo and 5 ⁇ l ligation buffer X10 and annealed at 60°C for ten minutes. 2 ⁇ l ligase was added and incubated overnight at 16°C. The ligation mixture was diluted by adding 140 ⁇ l TE. Amplification was carried out in a volume of 200 ⁇ l using R-Bgl-24 primer and 2 ⁇ l ligation product and repeated in twenty tubes for each sample. Before adding Taq DNA polymerase, the tubes were heated to 72°C for three minutes.
- PCR conditions were as follows: five minutes at 72°C, twenty cycles of one minute at 95°C and three minutes at 72°C, followed by ten minutes at 72°C. Every four reactions were combined, extracted with phenol/chloroform and precipitated. Amplified DNA was dissolved to a concentration of 0.5 ⁇ g/ ⁇ l and all samples were pooled. Subtraction: Tester DNA (20 ⁇ g) was digested with DpnII as above and separated on a 1.2% agarous gel. The DNA was extracted from the gel and 2 ⁇ g was ligated to J-Bgl-12 and J-Bgl24 oligos as described above for the R-oligos. The ligated Tester DNA was diluted to 1 Ong/ ⁇ l with TE. Driver DNA was digested with
- Amplification Amplification of subtracted DNA in a final volume of 200 ⁇ l as follows: Buffer, nucleotides and 20 ⁇ l of the diluted DNA were added, heated to
- C6 glioma cells were grown under normal conditions (Normoxia) or under oxygen deprivation conditions (Hypoxia) for eight hours. The cells were then harvested and cytoplasmic extracts were applied onto sucrose gradients. RNA was extracted from the fractions obtained from the sucrose gradient and pooled into polysomal and non-polysomal samples. Following reverse transcription, the differential display technique was applied using the primers Tl and PIO as set forth in Table 2. The PCR products were separated on a 5% acrylamide sequencing gel. The gel was then dried and exposed to X-ray film. The results are shown in Figure
- A shows an mRNA species apparent only in a non-polysomal fraction of cells after eight hours of hypoxia. This represents a potentially transcriptionally induced mRNA species which was still translationally repressed but which could be actively transcribed after prolonged hypoxia.
- B represents an mRNA species found in the non-polysomal fraction of cells grown under normal oxygen levels which was transferred into the polysomal fraction following hypoxia.
- the experimental cells were grown under both normal temperature (37°C) and heat shock temperature (43 °C) for four hours. The cells were then harvested and cytoplasmic extracts were obtained and RNA extracted therefrom. Then, the extracted RNA was analyzed utilizing GEM technology as disclosed above.
- Tables 3 and 4 demonstrate the utility of utilizing polysomal probes versus total mRNA probes in differential expression analysis to identify genes which are differentially expressed in response to a stimulus such as heat shock.
- a stimulus such as heat shock.
- Tables illustrate that fibronectin, pyruvate kinase, protein disulfide isomerese, poly(ADPribose) polymerase, thymopoietin, 90Kd heat shock protein, acylamino acid-releasing enzyme, ⁇ -spectrin, and pyruvate kinase were all identified as being differentially expressed utilizing a polysomal probe whereas, with the exception of fibronectin, the other proteins were not identified as being differentially expressed when a total mRNA probe was utilized.
- This example demonstrates the utility of the present invention for identifying translationally or differentially regulated genes which are regulated by a stress inducing element. Additionally, in Table 3, the results of heat shock differential gene expression analysis with both polysomal probes and total mRNA probes is provided. Table 3 illustrates that a number of differentially expressed genes were identified using a polysomal probe whereas when a total mRNA probe was used, these genes were not necessarily identified as being differentially expressed. Table 4 statistically illustrates the number of differentially expressed genes identified utilizing either total mRNA or polysomal mRNA as a probe. Table 4 clearly illustrates that polysomal mRNA probes yielded between two and greater than ten fold increases in the number of differentially expressed genes versus total mRNA probes.
- HEK-293 human (ATCC CRL-1573) cells were used as a model system for Polio virus 2A protease induced expression, since preliminary study indicated that 2 A protease enhances expression of IRES containing genes in this cell line.
- HEK-293 cells were co-transfected with CMV-LacI - (constructed by applicant using techniques known to those skilled in the art) in combination with either one of the Polio virus 2 A protease expression vectors PTK-OP3-WT2A, miniTK-WT2A, on PCIbb-LacI-Hyg (constructed by applicant on basis of vectors from Stratagene) as shown in Figures 3A-C, respectively.
- the Lad expression vector contained a hygromycin selectable marker
- the Polio virus 2A protease expression vector contained a neomycin selectable marker which enabled the isolation of clones resistant to both markers, presumably expressing both Lad repressor and Polio virus 2A proteins.
- Polio virus 2A protease expression Death assay - Resistant clones which grew after selection on hygromycin
- PCR is a very sensitive method, and was used to monitor the induction of the mRNA encoding for Polio virus 2A protease in HEK-293miniTK#l clones following IPTG treatment.
- mRNA was prepared from HEK-293 parental cells and HEK-293miniTK-2A clones following treatment with IPTG at different time points. The RNAs were subjected to the RT-PCR reaction using Polio virus 2A protease specific oligonucleotides:
- Polio virus 2A protease mRNA was not detected in HEK-293 parental cells, however it was induced following IPTG treatment and reached its highest level after 48 hours of IPTG treatment as shown in Figure 5.
- Analysis of 2 A protease activity p220 cleavage - A well characterized function of Polio virus 2A protease is the cleavage of the p220 protein (4F ⁇ translational factor), a component of the 40S ribosomal subunit. Cleavage of p220 yields three N-terminal cleavage products of 100-120KDa molecular weight due to post-translational modification.
- FIG. 6 demonstrates such an analysis in which HEK-293 miniTK2A#l clone and HEK-293TK2A#14 clone were induced for Polio virus 2A protease expression to generate cleavage products of p220.
- HEK-293 cell lysate was treated with Polio virus 2A protease produced by in vitro translation, and was found to generate identical cleavage products with the same mobility on 7% SDS PAGE as in the HEK-293 2A clones.
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
- MOLECULE TYPE other nucleic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97947522A EP0942969A1 (fr) | 1996-11-12 | 1997-11-12 | Procede d'identification des genes regules par traduction |
JP52285498A JP2002515754A (ja) | 1996-11-12 | 1997-11-12 | 翻訳的に制御される遺伝子の同定方法 |
IL12987297A IL129872A0 (en) | 1996-11-12 | 1997-11-12 | Method for identifying translationally regulated genes |
AU52580/98A AU5258098A (en) | 1996-11-12 | 1997-11-12 | Method for identifying translationally regulated genes |
CA002271068A CA2271068A1 (fr) | 1996-11-12 | 1997-11-12 | Procede d'identification des genes regules par traduction |
IL129872A IL129872A (en) | 1996-11-12 | 1999-05-10 | Method for identifying translationally regulated genes |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/748,130 US6013437A (en) | 1996-11-12 | 1996-11-12 | Method for identifying translationally regulated genes |
US94358697A | 1997-10-03 | 1997-10-03 | |
US08/943,586 | 1997-10-03 | ||
US08/748,130 | 1997-10-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998021321A1 true WO1998021321A1 (fr) | 1998-05-22 |
Family
ID=27114885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/020831 WO1998021321A1 (fr) | 1996-11-12 | 1997-11-12 | Procede d'identification des genes regules par traduction |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0942969A1 (fr) |
JP (1) | JP2002515754A (fr) |
AU (1) | AU5258098A (fr) |
CA (1) | CA2271068A1 (fr) |
IL (2) | IL129872A0 (fr) |
WO (1) | WO1998021321A1 (fr) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000005366A3 (fr) * | 1998-07-24 | 2000-06-15 | Univ Ottawa | Sequence ires du gene xiap et ses utilisations |
WO2000044896A1 (fr) * | 1999-01-26 | 2000-08-03 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Site d'entree ribosomique interne (ires), vecteur le contenant et utilisations correspondantes |
WO2000055323A1 (fr) * | 1999-03-16 | 2000-09-21 | Mitokor | Expression differentielle de produits geniques d'organites |
WO2000068423A3 (fr) * | 1999-05-05 | 2001-04-26 | European Molecular Biology Lab Embl | Efficacite predictive amelioree de l'analyse d'arn pour l'expression de proteines |
EP1012268A4 (fr) * | 1997-02-25 | 2001-11-28 | Qbi Entpr Ltd | Sequences d'ires conferant une grande efficacite de traduction et vecteurs d'expression contenant la sequence |
JP2002095483A (ja) * | 2000-09-25 | 2002-04-02 | Toyota Motor Corp | mRNAの潜在的翻訳制御因子のスクリーニング方法 |
WO2000060126A3 (fr) * | 1999-04-08 | 2002-06-20 | Sir Mortimer B Davis Jewish Ge | Bioanalyse quantitative d'expression de genes dans des microechantillons |
KR20020096559A (ko) * | 2001-06-21 | 2002-12-31 | 이준호 | 알코올에 의해 특이적으로 그 전사발현이 유도되거나저해되는 알코올 민감성 유전자 발굴 |
EP1169477A4 (fr) * | 1999-03-24 | 2003-01-02 | Quark Biotech Inc | Adnc codant pour des proteines secretees ou membranaires |
WO2001075159A3 (fr) * | 2000-03-31 | 2003-01-16 | Sir Mortimer B Davis Jewish Ge | Microechantillons de genes regulateurs |
WO2002066637A3 (fr) * | 2000-10-31 | 2003-05-22 | Hitachi Chemical Res Ct Inc | Methode de collecte et d'utilisation d'arnm nucleaire |
WO2003016527A3 (fr) * | 2001-08-14 | 2003-12-31 | Probiox Sa | Procede permettant de detecter un stress oxydatif et trousse destinee a la mise en oeuvre de ce procede |
US6764852B2 (en) | 1999-01-26 | 2004-07-20 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Internal ribosome entry site, vector containing same and uses thereof |
US7258976B2 (en) | 1997-12-22 | 2007-08-21 | Hitachi Chemical Co. Ltd. | Method of preparing cell lysate |
US7285199B2 (en) | 2000-10-31 | 2007-10-23 | Hitachi Chemical Research Center, Inc. | Apparatus and method for electrophoretic microspot concentration |
WO2012009644A3 (fr) * | 2010-07-16 | 2012-03-08 | Arizona Board Of Regents | Procédés pour identifier des éléments d'arn synthétiques et naturels qui améliorent la traduction des protéines |
WO2013031821A1 (fr) * | 2011-09-02 | 2013-03-07 | 国立大学法人奈良先端科学技術大学院大学 | Procédé de production de protéine utilisant des cellules de plante transformées |
US9163254B2 (en) | 2009-08-19 | 2015-10-20 | National University Corporation NARA Institute of Science and Technology | Recombinant DNA molecule encoding 5′ UTR capable of preventing inhibition of translation under environmental stresses |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995013369A1 (fr) * | 1993-11-12 | 1995-05-18 | The Scripps Research Institute | PROCEDE PERMETTANT L'IDENTIFICATION SIMULTANEE D'ARNm D'EXPRESSION DIFFERENTIELLE ET LA MESURE DE CONCENTRATIONS RELATIVES |
-
1997
- 1997-11-12 AU AU52580/98A patent/AU5258098A/en not_active Abandoned
- 1997-11-12 WO PCT/US1997/020831 patent/WO1998021321A1/fr not_active Application Discontinuation
- 1997-11-12 EP EP97947522A patent/EP0942969A1/fr not_active Withdrawn
- 1997-11-12 CA CA002271068A patent/CA2271068A1/fr not_active Abandoned
- 1997-11-12 JP JP52285498A patent/JP2002515754A/ja active Pending
- 1997-11-12 IL IL12987297A patent/IL129872A0/xx active IP Right Revival
-
1999
- 1999-05-10 IL IL129872A patent/IL129872A/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995013369A1 (fr) * | 1993-11-12 | 1995-05-18 | The Scripps Research Institute | PROCEDE PERMETTANT L'IDENTIFICATION SIMULTANEE D'ARNm D'EXPRESSION DIFFERENTIELLE ET LA MESURE DE CONCENTRATIONS RELATIVES |
Non-Patent Citations (7)
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6653132B1 (en) | 1997-02-25 | 2003-11-25 | Qbi Enterprises, Ltd. | IRES sequences with high translational efficiency and expression vectors containing the sequence |
EP1012268A4 (fr) * | 1997-02-25 | 2001-11-28 | Qbi Entpr Ltd | Sequences d'ires conferant une grande efficacite de traduction et vecteurs d'expression contenant la sequence |
US7258976B2 (en) | 1997-12-22 | 2007-08-21 | Hitachi Chemical Co. Ltd. | Method of preparing cell lysate |
US6171821B1 (en) | 1998-07-24 | 2001-01-09 | Apoptogen, Inc. | XIAP IRES and uses thereof |
WO2000005366A3 (fr) * | 1998-07-24 | 2000-06-15 | Univ Ottawa | Sequence ires du gene xiap et ses utilisations |
WO2000044896A1 (fr) * | 1999-01-26 | 2000-08-03 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Site d'entree ribosomique interne (ires), vecteur le contenant et utilisations correspondantes |
US6764852B2 (en) | 1999-01-26 | 2004-07-20 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Internal ribosome entry site, vector containing same and uses thereof |
WO2000055323A1 (fr) * | 1999-03-16 | 2000-09-21 | Mitokor | Expression differentielle de produits geniques d'organites |
EP1169477A4 (fr) * | 1999-03-24 | 2003-01-02 | Quark Biotech Inc | Adnc codant pour des proteines secretees ou membranaires |
WO2000060126A3 (fr) * | 1999-04-08 | 2002-06-20 | Sir Mortimer B Davis Jewish Ge | Bioanalyse quantitative d'expression de genes dans des microechantillons |
WO2000068423A3 (fr) * | 1999-05-05 | 2001-04-26 | European Molecular Biology Lab Embl | Efficacite predictive amelioree de l'analyse d'arn pour l'expression de proteines |
WO2001075159A3 (fr) * | 2000-03-31 | 2003-01-16 | Sir Mortimer B Davis Jewish Ge | Microechantillons de genes regulateurs |
JP2002095483A (ja) * | 2000-09-25 | 2002-04-02 | Toyota Motor Corp | mRNAの潜在的翻訳制御因子のスクリーニング方法 |
JP4723713B2 (ja) * | 2000-09-25 | 2011-07-13 | トヨタ自動車株式会社 | mRNAの潜在的翻訳制御因子のスクリーニング方法 |
US7374881B2 (en) | 2000-10-31 | 2008-05-20 | Hitachi Chemical Research Center, Inc. | Method for collecting and using nuclear mRNA |
WO2002066637A3 (fr) * | 2000-10-31 | 2003-05-22 | Hitachi Chemical Res Ct Inc | Methode de collecte et d'utilisation d'arnm nucleaire |
CN1294262C (zh) * | 2000-10-31 | 2007-01-10 | 日立化学研究中心 | 收集以及使用细胞核mRNA的方法 |
US7285199B2 (en) | 2000-10-31 | 2007-10-23 | Hitachi Chemical Research Center, Inc. | Apparatus and method for electrophoretic microspot concentration |
KR20020096559A (ko) * | 2001-06-21 | 2002-12-31 | 이준호 | 알코올에 의해 특이적으로 그 전사발현이 유도되거나저해되는 알코올 민감성 유전자 발굴 |
US7288374B2 (en) | 2001-08-14 | 2007-10-30 | Probiox Sa | Process for the detection of oxidative stress and kit for its implementation |
WO2003016527A3 (fr) * | 2001-08-14 | 2003-12-31 | Probiox Sa | Procede permettant de detecter un stress oxydatif et trousse destinee a la mise en oeuvre de ce procede |
BE1014949A3 (fr) * | 2001-08-14 | 2004-07-06 | Probiox | Procede de detection de stress oxydant et trousse pour sa mise en oeuvre. |
US9163254B2 (en) | 2009-08-19 | 2015-10-20 | National University Corporation NARA Institute of Science and Technology | Recombinant DNA molecule encoding 5′ UTR capable of preventing inhibition of translation under environmental stresses |
WO2012009644A3 (fr) * | 2010-07-16 | 2012-03-08 | Arizona Board Of Regents | Procédés pour identifier des éléments d'arn synthétiques et naturels qui améliorent la traduction des protéines |
WO2013031821A1 (fr) * | 2011-09-02 | 2013-03-07 | 国立大学法人奈良先端科学技術大学院大学 | Procédé de production de protéine utilisant des cellules de plante transformées |
JPWO2013031821A1 (ja) * | 2011-09-02 | 2015-03-23 | 国立大学法人 奈良先端科学技術大学院大学 | 形質転換植物細胞を用いたタンパク質製造方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2271068A1 (fr) | 1998-05-22 |
AU5258098A (en) | 1998-06-03 |
IL129872A0 (en) | 2000-02-29 |
JP2002515754A (ja) | 2002-05-28 |
IL129872A (en) | 2006-04-10 |
EP0942969A1 (fr) | 1999-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998021321A1 (fr) | Procede d'identification des genes regules par traduction | |
US5599672A (en) | Method of differential display of exposed mRNA by RT/PCR | |
US5262311A (en) | Methods to clone polyA mRNA | |
Liang et al. | Distribution and cloning of eukaryotic mRNAs by means of differential display: refinements and optimization | |
Liang et al. | Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction | |
EP0797685B1 (fr) | ANALYSE DE L'EXPRESSION DE GENES PAR MISE EN EVIDENCE DE FRAGMENTS DE RESTRICTION DE L'EXTREMITE 3' D'ADNc | |
AU2001276632B2 (en) | Methods of identification and isolation of polynucleotides containing nucleic acid differences | |
Miele et al. | Elimination of false positives generated through PCR re-amplification of differential display cDNA | |
EP0981609B1 (fr) | METHODE PERMETTANT DE CLONER DES ARNm ET D'AFFICHER DES TRANSCRITS A EXPRESSION DIFFERENTIELLE (DODETS) | |
US6066452A (en) | Multiplex selection technique for identifying protein-binding sites and DNA-binding proteins | |
Zeng et al. | Differential cDNA cloning by enzymatic degrading subtraction (EDS) | |
WO1997027330A1 (fr) | Procede de selection multiple pour identifier des sites de liaison avec une proteine pour des proteines se liant a l'adn | |
WO1997007244A1 (fr) | SEPARATION DE GENES AMPLIFIES, PAR HYBRIDATION SOUSTRACTIVE D'ADNc | |
EP1105527A1 (fr) | Procede d'identification de motifs de transcription de genes | |
US5922535A (en) | Identifying sequence differences in nucleic acid populations | |
US20020037511A1 (en) | Method for identifying genes | |
US6013437A (en) | Method for identifying translationally regulated genes | |
Yoshikawa et al. | Differential display with carboxy-X-rhodamine-labeled primers and the selection of differentially amplified cDNA fragments without cloning | |
Mohanty et al. | Analysis of RNA decay, processing, and polyadenylation in Escherichia coli and other prokaryotes | |
AU783310B2 (en) | Genetic markers of toxicity, preparation and uses thereof | |
Matin et al. | Multidimensional differential display via ion-pair reversed-phase denaturing high-performance liquid chromatography | |
EP1144687A2 (fr) | Procede d'isolement par affinite d'arn venant d'etre synthetise | |
KR19980037261A (ko) | 랜덤 프라이머 집합을 이용한 mRNA의 증폭방법과 이의 용도 | |
Eriksson et al. | Protocol for using signal peptide differential display and representational difference analysis to isolate differentially expressed cDNAs from fetal mouse brain | |
Zeng et al. | Direct characterization, enrichment and sequencing of differential displayed cDNA sequences |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2271068 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 52580/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997947522 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09297999 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997947522 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997947522 Country of ref document: EP |